Clinical trials for preventative HIV gel

By Bizclik Editor

 

Scientists in South Africa are holding clinical trials to test a gel they believe could reduce the risk of women being infected with HIV.

The gel is being tested at seven centres and according to Professor Helen Rees, Executive Director of the Wits Reproductive Health and HIV Institute, is the first South African team of scientists to head a multi-site trial.

Previously, multi-site trials were led by international scientists working with local peers.

 

READ MORE FROM THE WDM CONTENT NETWORK:

To read the latest edition of African Business Review, click here.

 

"The planning for the Facts study is well under way and we hope to be in the field by August," said Rees.

The Tenofovir vaginal gel is seen as a positive breakthrough for HIV prevention. It proved 39 percent effective at protecting young women from HIV and halved the risk of Herpes HSV-2, according to the Caprisa 004 study in KwaZulu-Natal.

The Facts study aims to confirm these results.

Share

Featured Articles

Top 10 metaverse projects in the UAE, including world firsts

As Accenture predicts the metaverse will fuel a US$1 trilion commerce opportunity by 2025, we round up 10 pioneering metaverse projects in the UAE

PwC’s survey shows Middle East CEOs remain upbeat on growth

CEOs in the Middle East are far more optimistic about regional growth than those in North America and Europe, according to PwC’s annual survey

Opinion: “Why we must tackle the digital skills crisis"

Upskilling for the digital world isn’t complicated but it is urgent, argues Tom Moore, CEO of WithYouWithMe – a social impact tech firm founded by veterans

5 Mins With: Kathryn Kaminsky Vice Chair Trust Solutions PwC

Leadership & Strategy

Survey: The Future of Cloud Security in the Middle East

Technology

Deloitte US Chief Purpose Officer on driving impact at scale

Leadership & Strategy